Bronchiectasis is a long-term lung disease in which the airways become widened and scarred, trapping mucus and leading to chronic cough, repeated infections and flare-ups. It is far more common than once thought: hundreds of thousands of US adults are estimated to have it, with tens of thousands newly diagnosed each year. Until 2025 there was no approved drug; treatment relied on airway clearance, long-term antibiotics and treating flare-ups. Brensocatib, approved in August 2025, targets neutrophil inflammation, and several similar drugs are in phase 3.
- 35studies open or running
- 4phase 3 trials
- 460papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
The first approved drugHappened 0.79 flare-up rate ratio
Brensocatib cut the flare-up rate (rate ratio 0.79 vs placebo) and kept 48.5% flare-free for a year vs 40.3%.
0.79: rate ratio for flare-ups vs placebo (10 mg).
A whole drug class emergingHappened 0.41 flare-up rate ratio
Other DPP-1 and cathepsin C blockers also reduced flare-ups in phase 2.
0.41: rate ratio for flare-ups vs placebo (40 mg).
Mucus thinners questionedHappened 0.76 flare-ups per year
Hypertonic saline (0.76 vs 0.98 flare-ups a year) and carbocisteine did not significantly reduce flare-ups.
0.76: flare-ups per year with hypertonic saline, vs 0.98 without.
-
6 months
by May 2027
HSK31858 phase 3 resultsLikely
Haisco's phase 3 (669 people) finishes November 2026.
-
12 months
by Nov 2027
AIRTIVITY resultsPossible 0.66 hazard ratio (phase 2)
Boehringer's BI 1291583 phase 3 (1,755 people) is due June 2027.
0.66: hazard ratio for first flare-up at 2.5 mg.
EnsifentrinePossible
A nebulized COPD drug that opens airways and reduces inflammation is in a 284-person trial due September 2027.
-
3 years
by late 2029
More anti-inflammatory approachesLong shot
UCB's galvokimig (300 people, due February 2029) and CSL's inhaled CSL787 (180 people, due May 2029) target inflammation and infection differently.
-
5 years
by late 2031
Treatment matched to the causeLong shot
Trials increasingly match treatment to features such as eosinophils, fungal sensitization or Pseudomonas infection.
The research paths
Neutrophil-targeting pills
0.79 flare-up rate ratioDetails and 3 trialsHide
DPP-1 and cathepsin C inhibitors that calm airway inflammation.
WatchHSK31858 phase 3; AIRTIVITY.
Inhaled and novel anti-inflammatories
Details and 3 trialsHide
Ensifentrine, antibodies and inhaled immunoglobulin.
WatchEnsifentrine trial.
Mucus and infection
0.76 flare-ups per yearDetails and 2 trialsHide
Mucus thinners, antifungals and inhaled antimicrobials.
WatchBAIT.
Borrowed from other conditions
From COPD
Ensifentrine
Phase 2
An inhaled PDE3/PDE4 inhibitor approved for COPD in 2024.
From Allergic bronchopulmonary aspergillosis
Itraconazole
Phase 3
An antifungal tested in people sensitized to Aspergillus.
From Primary immune deficiency
Inhaled immunoglobulin (CSL787)
Phase 2
Antibodies from donated plasma, usually given by vein, here inhaled into the airways.
Open to join now
-
Bronchiectasis
BI 1291583
Locations and eligibility → -
Bronchiectasis
Nebulized ensifentrine
Locations and eligibility → -
Bronchiectasis
CSL787
Locations and eligibility → -
Bronchiectasis
Galvokimig
Locations and eligibility →
See every recruiting Bronchiectasis trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Mucus thinners do not significantly cut flare-ups
CLEAR, NEJM.
FDA approves brensocatib, first bronchiectasis drug
ASPEN, NEJM.
Standard treatment today
- DiagnosisCT scan; tests for underlying causes (immune deficiency, ciliary disorders, NTM infection, ABPA).
- Daily careAirway clearance exercises, exercise, vaccinations.
- Frequent flare-upsBrensocatib, long-term macrolide antibiotics, or inhaled antibiotics for Pseudomonas.
- Flare-ups14 days of antibiotics chosen by sputum culture.
How to read this page, and sourcesHow to read this page, and sources
- This page covers bronchiectasis not caused by cystic fibrosis, which has its own treatments.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Bronchiectasis trials recruiting now →